Design Therapeutics, Inc. DSGN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $14.38M-6.5% | $13.43M+10.4% | $14.59M+22.8% | $15.74M+49.7% | $15.38M+56.9% | ||
| $5.33M+5.7% | $4.74M+4.6% | $4.72M+8.1% | $5.83M+28.8% | $5.04M+9.6% | ||
| $19.71M-3.5% | $18.17M+8.8% | $19.31M+18.9% | $21.57M+43.4% | $20.42M+41.8% | ||
| $19.71M-3.5% | $18.17M+8.8% | $19.31M+18.9% | $21.57M+43.4% | $20.42M+41.8% | ||
| -$19.71M+3.5% | -$18.17M-8.8% | -$19.31M-18.9% | -$21.57M-43.4% | -$20.42M-41.8% | ||
| $2.07M-23.4% | $2.17M-28.6% | $2.31M-27.8% | $2.49M-23.5% | $2.7M-18.0% | ||
| —— | —— | —— | —— | —— | ||
| -$17.64M+0.4% | -$16M-17.2% | -$17M-30.4% | -$19.08M-61.8% | -$17.72M-59.5% | ||
| -$0.29+6.5% | -$0.27-12.5% | -$0.30-30.4% | -$0.34-61.9% | -$0.31-55.0% | ||
| -$0.29+6.5% | -$0.27-12.5% | -$0.30-30.4% | -$0.34-61.9% | -$0.31-55.0% | ||
| 61.4M+8.2% | 57.3M+1.3% | 57M+0.6% | 56.9M+0.5% | 56.8M+0.5% | ||
| 61.4M+8.2% | 57.3M+1.3% | 57M+0.6% | 56.9M+0.5% | 56.8M+0.5% | ||
| -$19.71M+3.5% | -$18.17M-8.8% | -$19.31M-18.9% | -$21.57M-43.4% | -$20.42M-41.8% | ||
| -$19.55M+3.5% | -$18.01M-8.9% | -$19.16M-19.0% | -$21.42M-43.8% | -$20.26M-42.1% | ||
| -$19.55M+3.5% | -$18.01M-8.9% | -$19.16M-19.0% | -$21.42M-43.8% | -$20.26M-42.1% | ||
| -$19.71M+3.5% | -$18.17M-8.8% | -$19.31M-18.9% | -$21.57M-43.4% | -$20.42M-41.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Design Therapeutics, Inc. profitable?
- Design Therapeutics, Inc. is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -3663.7% net margin.
- What is Design Therapeutics, Inc.'s earnings per share?
- Design Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.20.
- Where does Design Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.